136 related articles for article (PubMed ID: 37879694)
21. EQ-5D-Y Value Set for Germany.
Kreimeier S; Mott D; Ludwig K; Greiner W;
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
[TBL] [Abstract][Full Text] [Related]
22. Measurement properties and responsiveness of the EQ-5D-Y-5L compared to the EQ-5D-Y-3L in children and adolescents receiving acute orthopaedic care.
Verstraete J; Marthinus Z; Dix-Peek S; Scott D
Health Qual Life Outcomes; 2022 Feb; 20(1):28. PubMed ID: 35177084
[TBL] [Abstract][Full Text] [Related]
23. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
[TBL] [Abstract][Full Text] [Related]
24. Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values.
Selivanova A; Buskens E; Krabbe PFM
Pharmacoeconomics; 2018 Jun; 36(6):715-725. PubMed ID: 29623559
[TBL] [Abstract][Full Text] [Related]
25. Preference heterogeneity in health valuation: a latent class analysis of the Peru EQ-5D-5L values.
Karim S; Craig BM; Tejada RA; Augustovski F
Health Qual Life Outcomes; 2023 Jan; 21(1):1. PubMed ID: 36593473
[TBL] [Abstract][Full Text] [Related]
26. Valuing EQ-5D-Y: the current state of play.
Devlin N; Pan T; Kreimeier S; Verstraete J; Stolk E; Rand K; Herdman M
Health Qual Life Outcomes; 2022 Jul; 20(1):105. PubMed ID: 35794607
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Preferences and Data Quality between Discrete Choice Experiments Conducted in Online and Face-to-Face Respondents.
Jiang R; Pullenayegum E; Shaw JW; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
Med Decis Making; 2023 Aug; 43(6):667-679. PubMed ID: 37199407
[TBL] [Abstract][Full Text] [Related]
28. Preference Paths and Their Kaizen Tasks for Small Samples.
Craig BM; Rand K; Hartman JD
Patient; 2022 Mar; 15(2):187-196. PubMed ID: 34327605
[TBL] [Abstract][Full Text] [Related]
29. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
30. Why Do Adults Value EQ-5D-Y-3L Health States Differently for Themselves Than for Children and Adolescents: A Think-Aloud Study.
Reckers-Droog V; Karimi M; Lipman S; Verstraete J
Value Health; 2022 Jul; 25(7):1174-1184. PubMed ID: 35168891
[TBL] [Abstract][Full Text] [Related]
31. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
32. Valuation of the EQ-5D-3L in Russia.
Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
[TBL] [Abstract][Full Text] [Related]
33. In a Child's Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy Perspectives.
Lipman SA; Essers BAB; Finch AP; Sajjad A; Stalmeier PFM; Roudijk B
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):181-192. PubMed ID: 36255560
[TBL] [Abstract][Full Text] [Related]
34. Experience-based health state valuation using the EQ VAS: a register-based study of the EQ-5D-3L among nine patient groups in Sweden.
Teni FS; Burström K; Devlin N; Parkin D; Rolfson O;
Health Qual Life Outcomes; 2023 Apr; 21(1):34. PubMed ID: 37038172
[TBL] [Abstract][Full Text] [Related]
35. Measuring health-related quality of life in the general population and Roma communities in Romania: study protocol for two cross-sectional studies.
Olariu E; Paveliu MS; Baican E; Oluboyede Y; Vale L; Niculescu-Aron IG
BMJ Open; 2019 Aug; 9(8):e029067. PubMed ID: 31427330
[TBL] [Abstract][Full Text] [Related]
36. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
38. Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L.
Chemli J; Drira C; Felfel H; Roudijk B; Al Sayah F; Kouki M; Kooli A; Razgallah Khrouf M
Qual Life Res; 2021 May; 30(5):1445-1455. PubMed ID: 33447958
[TBL] [Abstract][Full Text] [Related]
39. Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data.
Ramos-Goñi JM; Oppe M; Estévez-Carrillo A; Rivero-Arias O;
Value Health; 2022 May; 25(5):835-843. PubMed ID: 35500952
[TBL] [Abstract][Full Text] [Related]
40. An EQ-5D-Y-3L Value Set for Belgium.
Dewilde S; Roudijk B; Tollenaar NH; Ramos-Goñi JM
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):169-180. PubMed ID: 36316544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
